Role of Phosphodiesterases in Biology and Pathology 2.0

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 May 25

PMID 38791377

Authors

Mauro Giorgi

Manuela Pellegrini

Mara Massimi

Affiliations

Soon will be listed here.

Abstract

Phosphodiesterases (PDEs) are ubiquitous enzymes that hydrolyse cAMP and cGMP second messengers temporally, spatially, and integratedly according to their expression and compartmentalization inside the cell [...].

Citing Articles

RNA Editing Signatures Powered by Artificial Intelligence: A New Frontier in Differentiating Schizophrenia, Bipolar, and Schizoaffective Disorders.

Checa-Robles F, Salvetat N, Cayzac C, Menhem M, Favier M, Vetter D Int J Mol Sci. 2024; 25(23).

PMID: 39684694 PMC: 11641080. DOI: 10.3390/ijms252312981.

References

Lugnier C . The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches. Int J Mol Sci. 2022; 23(18). PMC: 9502408. DOI: 10.3390/ijms231810616. View

Lee K, Chang W, Chen X, Valiyaveettil J, Ramirez-Alcantara V, Gavin E . Suppression of Colon Tumorigenesis in Mutant Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin. Cancer Prev Res (Phila). 2021; 14(11):995-1008. PMC: 8916418. DOI: 10.1158/1940-6207.CAPR-21-0208. View

Hsien Lai S, Zervoudakis G, Chou J, Gurney M, Quesnelle K . PDE4 subtypes in cancer. Oncogene. 2020; 39(19):3791-3802. PMC: 7444459. DOI: 10.1038/s41388-020-1258-8. View

West T, Wang Q, Deng B, Zhang Y, Barbagallo F, Reddy G . Phosphodiesterase 5 Associates With β2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts. J Am Heart Assoc. 2019; 8(15):e012273. PMC: 6761630. DOI: 10.1161/JAHA.119.012273. View

Mukohda M, Fang S, Wu J, Agbor L, Nair A, Ibeawuchi S . RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity. J Clin Invest. 2019; 129(6):2318-2332. PMC: 6546477. DOI: 10.1172/JCI123462. View

Manfra O, Calamera G, Froese A, Arunthavarajah D, Surdo N, Meier S . CNP regulates cardiac contractility and increases cGMP near both SERCA and TnI: difference from BNP visualized by targeted cGMP biosensors. Cardiovasc Res. 2021; 118(6):1506-1519. PMC: 9074987. DOI: 10.1093/cvr/cvab167. View

Kyurkchieva E, Baillie G . Short PDE4 Isoforms as Drug Targets in Disease. Front Biosci (Landmark Ed). 2023; 28(7):133. DOI: 10.31083/j.fbl2807133. View

Wiest R, Groszmann R . The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002; 35(2):478-91. DOI: 10.1053/jhep.2002.31432. View

Barnes H, Brown Z, Burns A, Williams T . Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019; 1:CD012621. PMC: 6354064. DOI: 10.1002/14651858.CD012621.pub2. View

10.

Turco L, Garcia-Tsao G . Portal Hypertension: Pathogenesis and Diagnosis. Clin Liver Dis. 2019; 23(4):573-587. DOI: 10.1016/j.cld.2019.07.007. View

11.

Lomas O, Zaccolo M . Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotides. Physiology (Bethesda). 2014; 29(2):141-9. PMC: 3949206. DOI: 10.1152/physiol.00040.2013. View

12.

Campolo F, Pofi R, Venneri M, Isidori A . Priming metabolism with the type 5 phosphodiesterase: the role of cGMP-hydrolyzing enzymes. Curr Opin Pharmacol. 2021; 60:298-305. DOI: 10.1016/j.coph.2021.08.007. View

13.

Samidurai A, Xi L, Das A, Kukreja R . Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. Annu Rev Pharmacol Toxicol. 2022; 63:585-615. DOI: 10.1146/annurev-pharmtox-040122-034745. View

14.

Liu Y, Chen J, Fontes S, Bautista E, Cheng Z . Physiological and pathological roles of protein kinase A in the heart. Cardiovasc Res. 2021; 118(2):386-398. PMC: 8803072. DOI: 10.1093/cvr/cvab008. View

15.

Maurice D, Ke H, Ahmad F, Wang Y, Chung J, Manganiello V . Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014; 13(4):290-314. PMC: 4155750. DOI: 10.1038/nrd4228. View

16.

Bondarev A, Attwood M, Jonsson J, Chubarev V, Tarasov V, Liu W . Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. Front Pharmacol. 2022; 13:1057083. PMC: 9731127. DOI: 10.3389/fphar.2022.1057083. View

17.

Shakur Y, de Koning H, Ke H, Kambayashi J, Seebeck T . Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases. Handb Exp Pharmacol. 2011; (204):487-510. DOI: 10.1007/978-3-642-17969-3_20. View

18.

Giorgi M, Leonetti C, Citro G, Augusti-Tocco G . In vitro and in vivo inhibition of SK-N-MC neuroblastoma growth using cyclic nucleotide phosphodiesterase inhibitors. J Neurooncol. 2001; 51(1):25-31. DOI: 10.1023/a:1006489020190. View

19.

Ragusa F, Panera N, Cardarelli S, Scarsella M, Bianchi M, Biagioni S . Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma. Cancers (Basel). 2021; 13(9). PMC: 8125776. DOI: 10.3390/cancers13092182. View

20.

De Arcangelis V, Strimpakos G, Gabanella F, Corbi N, Luvisetto S, Magrelli A . Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy. J Cell Physiol. 2015; 231(1):224-32. DOI: 10.1002/jcp.25075. View